Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.
Also called NCT04491695
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 420 participants
- Sponsor
- Registry
-
NCT04491695
-
- Other papers using this trial's data
- Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial
- Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial
- Stroke etiology was associated with tirofiban efficacy in acute ischemic stroke without endovascular treatment: A pre-specified subgroup analysis of the TREND trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04491695. Randomized; single masking; primary purpose treatment. Start 2020-09-12 (actual); primary completion 2022-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
- Acronym
- TREND
- Condition
- Acute Stroke
- Intervention (Drug)
- Tirofiban Hydrochloride
- Intervention (Drug)
- Oral antiplatelet
- Lead sponsor
- Capital Medical University
Record details
- Record id
cardio:ct-nct04491695- Content hash
997e47c5a7d0029477bb85de6295948561cad3148a6cd389e241f6edf926c952